RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Ultragenyx Pharmaceutical Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$15.07+0.53 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
Ultragenyx Pharmaceutical Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $369.00M | $285.00M | $180.00M | $118.93M | $77.02M | $38.72M | $20.22M | $9.80M | $476.00K | $133.00K | 54.8% | +29.5% |
| Royalty revenue | $304.00M | $275.00M | $183.00M | $21.69M | $17.95M | $13.00M | – | – | – | – | 45.2% | +10.5% |
| Collaboration and license | $0 | $0 | $71.00M | $222.71M | $256.44M | $219.32M | $83.49M | $41.69M | $2.14M | – | 0.0% | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $377.00M | $340.00M | $307.00M | $281.09M | $301.11M | $237.67M | $86.44M | $45.34M | – | – | 56.0% | +10.9% |
| Latin America | $170.00M | $131.00M | $77.00M | $44.71M | $23.64M | $12.05M | – | – | – | – | 25.3% | +29.8% |
| Europe, Middle East, and Africa | $108.00M | $80.00M | $48.00M | $36.37M | – | – | – | – | – | – | 16.0% | +35.0% |
| Asia-Pacific | $18.00M | $9.00M | $2.00M | $1.16M | – | – | – | – | – | – | 2.7% | +100.0% |
| Europe | – | – | $47.53M | $36.37M | $26.66M | $21.32M | $12.09M | $5.29M | $323.00K | $133.00K | – | – |
| United States | – | – | – | – | – | – | $86.44M | $45.34M | $2.29M | – | – | – |
| All other | – | – | – | – | $23.64M | $12.05M | $5.19M | $863.00K | – | – | – | – |
| Japan | – | – | $2.22M | $1.16M | $0 | $0 | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Ultragenyx Pharmaceutical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.